Format

Send to

Choose Destination
J Antimicrob Chemother. 2003 Oct;52(4):656-62. Epub 2003 Sep 12.

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.

Author information

1
The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Infectious Diseases (7881), 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.

Abstract

OBJECTIVES:

AmBisome and micafungin were used alone and in combination in a series of studies designed to identify any additive or antagonistic effects of combination antifungal therapy.

METHODS:

Immune-suppressed mice were infected either intravenously or intranasally with Aspergillus fumigatus. Micafungin, liposomal amphotericin B or both drugs together were administered for 7 days. Parameters of efficacy included survival and tissue burden of A. fumigatus.

RESULTS:

Whilst each drug was effective in murine aspergillosis, additive effects were observed only in reduction of tissue burden in limited experimental conditions. No antagonism was seen.

CONCLUSIONS:

The present studies neither encourage nor discourage clinical use of combination therapy. Clinical trials are suggested before combined therapy is routinely adopted.

PMID:
12972452
DOI:
10.1093/jac/dkg425
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center